P/E ratio for Ionis Pharmaceuticals (IONS)
P/E ratio as of April 2024 (TTM): -14.5
According to Ionis Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -14.4774. At the end of 2022 the company had a P/E ratio of -19.9.
P/E ratio history for Ionis Pharmaceuticals from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -19.9 | -86.93% |
| 2021 | -152 | 728.83% |
| 2020 | -18.4 | -164.42% |
| 2019 | 28.5 | 4.89% |
| 2018 | 27.2 | -97.3% |
| 2017 | > 1000 | -1614.36% |
| 2016 | -66.4 | -21.69% |
| 2015 | -84.8 | -53.28% |
| 2014 | -182 | 141.57% |
| 2013 | -75.2 | 368.01% |
| 2012 | -16.1 | 89.35% |
| 2011 | -8.48 | -48.03% |
| 2010 | -16.3 | -333.6% |
| 2009 | 6.99 | -109.36% |
| 2008 | -74.6 | 658.16% |
| 2007 | -9.84 | -46% |
| 2006 | -18.2 | 307.03% |
| 2005 | -4.48 | 91.29% |
| 2004 | -2.34 | -38.05% |
| 2003 | -3.78 | -22.58% |
| 2002 | -4.88 | -62.16% |
| 2001 | -12.9 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Nymox Pharmaceutical NYMX | -3.33 | -76.98% | Bahamas |
 NRC Health
NRC | 28.8 | -298.63% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.